A Model to Predict Prognosis of Renal Cell Clear Cell Carcinoma Based on 3 Angiogenesis-related Long Non-coding RNAs

Overview

Journal J Cancer

Specialty Oncology

Date 2024 May 31

PMID 38817877

Authors

Guo Chen

Tiansheng Zhang

Feng Li

Chi Cui

Zhiyong Huang

Xin Gou

Yajun Song

Yang Li

Affiliations

Soon will be listed here.

Abstract

Tumor angiogenesis is closely related to the progression of clear cell renal cell carcinoma (ccRCC). Long non-coding RNAs (lncRNAs) regulating angiogenesis could be potential biomarkers for predicting ccRCC prognosis. With this study, we aimed to construct a prognostic model based on lncRNAs and explore its underlying mechanisms. RNA data and clinical information were obtained from The Cancer Genome Atlas (TCGA) database. Angiogenesis-related genes (ARGs) were extracted from the Molecular Signatures database. Pearson correlation and LASSO and COX regression analyses were performed to identify survival-related AR-lncRNAs (sAR-lncRNAs) and construct a prognostic model. The predictive power of the prognostic model was verified according to Kaplan‒Meier curve, receiver operating characteristic (ROC) curve and nomogram analyses. The correlation between the prognostic model and clinicopathological characteristics was assessed via univariate and multivariate analyses. Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis was subsequently performed to elucidate the mechanisms of the sAR-lncRNAs. In vitro qPCR, immunohistochemistry, migration and invasion assays were conducted to confirm the angiogenic function of sAR-lncRNAs. Three sAR-lncRNAs were used to construct a prognostic model. The model was moderately accurate in predicting 1- , 3- and 5-year ccRCC prognosis, and the risk score according to this model was closely related to clinicopathological characteristics such as T grade and T stage. A nomogram was constructed to precisely estimate the overall survival of ccRCC patients. KEGG enrichment analysis indicated that the MAPK and Notch pathways were highly enriched in high-risk patients. Additionally, we found that the expression of the lncRNAs AC005324.4 and AC104964.4 in the prognostic model was lower in ccRCC cell lines and cancer tissues than in the HK-2 cell line and paracancerous tissues, while the expression of the lncRNA AC087482.1 showed the opposite trend. In a coculture model, knockdown of lncRNA AC005324.4 and lncRNA AC104964.4 significantly promoted the migration and invasion of human umbilical vein endothelial cells (HUVECs), but siR-AC087482.1 transfection alleviated these effects. We constructed a prognostic model based on 3 sAR-lncRNAs and validated its value in clinicopathological characteristics and prognostic prediction of ccRCC patients, providing a new perspective for ccRCC treatment decision making.

References

Butti R, Das S, Gunasekaran V, Yadav A, Kumar D, Kundu G . Receptor tyrosine kinases (RTKs) in breast cancer: signaling, therapeutic implications and challenges. Mol Cancer. 2018; 17(1):34. PMC: 5817867. DOI: 10.1186/s12943-018-0797-x. View

Xing T, He H . Epigenomics of clear cell renal cell carcinoma: mechanisms and potential use in molecular pathology. Chin J Cancer Res. 2016; 28(1):80-91. PMC: 4779762. DOI: 10.3978/j.issn.1000-9604.2016.02.09. View

Li X, Kuang Q, Peng M, Yang K, Luo P . Basement Membrane-Associated lncRNA Risk Model Predicts Prognosis and Guides Clinical Treatment in Clear Cell Renal Cell Carcinoma. Biomedicines. 2023; 11(10). PMC: 10604562. DOI: 10.3390/biomedicines11102635. View

Xu Z, Peng B, Liang Q, Chen X, Cai Y, Zeng S . Construction of a Ferroptosis-Related Nine-lncRNA Signature for Predicting Prognosis and Immune Response in Hepatocellular Carcinoma. Front Immunol. 2021; 12:719175. PMC: 8484522. DOI: 10.3389/fimmu.2021.719175. View

Harrington L, Sainson R, Williams C, Taylor J, Shi W, Li J . Regulation of multiple angiogenic pathways by Dll4 and Notch in human umbilical vein endothelial cells. Microvasc Res. 2007; 75(2):144-54. DOI: 10.1016/j.mvr.2007.06.006. View

Gao S, Wang Y, Xu Y, Liu S . An Angiogenesis-Related lncRNA Signature Is Associated with Prognosis and Tumor Immune Microenvironment in Breast Cancer. J Pers Med. 2023; 13(3). PMC: 10057494. DOI: 10.3390/jpm13030513. View

Alvarez Ballesteros P, Chamorro J, Roman-Gil M, Pozas J, Gomez Dos Santos V, Granados A . Molecular Mechanisms of Resistance to Immunotherapy and Antiangiogenic Treatments in Clear Cell Renal Cell Carcinoma. Cancers (Basel). 2021; 13(23). PMC: 8656474. DOI: 10.3390/cancers13235981. View

Valdes-Mora F, Clark S . Prostate cancer epigenetic biomarkers: next-generation technologies. Oncogene. 2014; 34(13):1609-18. DOI: 10.1038/onc.2014.111. View

Herman A, Tsitsipatis D, Gorospe M . Integrated lncRNA function upon genomic and epigenomic regulation. Mol Cell. 2022; 82(12):2252-2266. PMC: 9219586. DOI: 10.1016/j.molcel.2022.05.027. View

10.

Pang Y, Wang Y, Zhou X, Ni Z, Chen W, Liu Y . Cuproptosis-Related LncRNA-Based Prediction of the Prognosis and Immunotherapy Response in Papillary Renal Cell Carcinoma. Int J Mol Sci. 2023; 24(2). PMC: 9863050. DOI: 10.3390/ijms24021464. View

11.

Deng Y, Guo K, Tang Z, Feng Y, Cai S, Ye J . Identification and experimental validation of a tumor-infiltrating lymphocytes-related long noncoding RNA signature for prognosis of clear cell renal cell carcinoma. Front Immunol. 2022; 13:1046790. PMC: 9730408. DOI: 10.3389/fimmu.2022.1046790. View

12.

Mlcochova H, Machackova T, Rabien A, Radova L, Fabian P, Iliev R . Epithelial-mesenchymal transition-associated microRNA/mRNA signature is linked to metastasis and prognosis in clear-cell renal cell carcinoma. Sci Rep. 2016; 6:31852. PMC: 4994011. DOI: 10.1038/srep31852. View

13.

Comandone A, Vana F, Comandone T, Tucci M . Antiangiogenic Therapy in Clear Cell Renal Carcinoma (CCRC): Pharmacological Basis and Clinical Results. Cancers (Basel). 2021; 13(23). PMC: 8656563. DOI: 10.3390/cancers13235896. View

14.

Peters I, Gebauer K, Dubrowinskaja N, Atschekzei F, Kramer M, Hennenlotter J . GATA5 CpG island hypermethylation is an independent predictor for poor clinical outcome in renal cell carcinoma. Oncol Rep. 2014; 31(4):1523-30. PMC: 3975988. DOI: 10.3892/or.2014.3030. View

15.

Gong Q, Huang X, Chen X, Zhang L, Zhou C, Li S . Construction and validation of an angiogenesis-related lncRNA prognostic model in lung adenocarcinoma. Front Genet. 2023; 14:1083593. PMC: 10043447. DOI: 10.3389/fgene.2023.1083593. View

16.

Han C, Zhang C, Wang H, Li K, Zhao L . Angiogenesis-related lncRNAs predict the prognosis signature of stomach adenocarcinoma. BMC Cancer. 2021; 21(1):1312. PMC: 8653638. DOI: 10.1186/s12885-021-08987-y. View

17.

Babina I, Turner N . Advances and challenges in targeting FGFR signalling in cancer. Nat Rev Cancer. 2017; 17(5):318-332. DOI: 10.1038/nrc.2017.8. View

18.

Makino T, Kadomoto S, Izumi K, Mizokami A . Epidemiology and Prevention of Renal Cell Carcinoma. Cancers (Basel). 2022; 14(16). PMC: 9406474. DOI: 10.3390/cancers14164059. View

19.

Wang Y, Liu C, Chen Y, Yang B, Chen X, Ma G . An angiogenesis-related lncRNA signature predicts the immune microenvironment and prognosis of breast cancer. Aging (Albany NY). 2023; 15(15):7616-7636. PMC: 10457060. DOI: 10.18632/aging.204930. View

20.

Campi R, Rebez G, Klatte T, Roussel E, Ouizad I, Ingels A . Effect of smoking, hypertension and lifestyle factors on kidney cancer - perspectives for prevention and screening programmes. Nat Rev Urol. 2023; 20(11):669-681. DOI: 10.1038/s41585-023-00781-8. View